This paper covers a detail design and cost (to an accuracy of +/- 20 percent) for a new manufacturing facility to produce DNA vaccines to be built on a greenfield site. Applied current good manufacturing practice (cGMP) and complied with all the regulatory guidelines set up by various agencies.
The demand for DNA vaccines in large quantities at high purity for gene therapy is on the increase. As it helps to stimulate antibodies production in human and provide immune protection against many diseases such as cancer, malaria, HIV and other diseases and have potential advantages over conventional vaccines.
Table of Contents
1.0 Introduction
1.1 Aims/objective
2.0 Detail of the process
2.1 Process description
2.2 Raw material required
2.3 Equipment required
2.4 Staff Involved
3.0 Design of Manufacturing facility
3.1 Plant location
3.2 Plant layout
3.21 Layout of the Plant site appendix 1
3.22 Layout of the Production House appendix 2
3.3 Manufacturing Flow
3.4 Room Specification data sheets appendix 3
4.0 Plant Services, Systems and Utilities
4.1 Heating, ventilation and air-conditioning (HVAC) system
4.2 Water
4.3 Clean steam
4.4 Heat and power
4.5 Cleaning Systems
4.51 Clean in Plane (CIP)
4.52 Sterilise in Place (SIP)
4.6 Cleanrooms
4.7 Process control & instrumentation
Instrumentation
5.0 Process Validation and cGMP
5.1 Process Validation
6.0 Gannt Chart
7.0 Costing
8.0 Conclusion
9.0 References
Research Objective and Scope
The primary objective of this report is to provide a comprehensive conceptual design and economic evaluation for a new, large-scale DNA vaccine manufacturing facility. The work seeks to establish a manufacturing environment that adheres to strict regulatory guidelines and current Good Manufacturing Practice (cGMP), while ensuring economic viability through optimized plant design and efficient production processes.
- Detailed process design for commercial pDNA production (fermentation to purification).
- Layout planning for contamination control and optimized material/personnel flow.
- Design of critical plant services, including HVAC, water treatment, and cleaning systems.
- Economic analysis covering capital costs, operating expenses, and return on investment.
- Strategic project scheduling using a fast-track approach for efficient construction and validation.
Excerpt from the Book
3.1 Plant location
The location of the drug production manufacturing facility is crucial to its profitability as it can be affected by raw material supply, climate, transportation, utilities and services, etc.
Site selection
The DNA vaccine plant will be located in southern England, Slough. This is chosen because the site is relatively near to greater London which can create huge advantages which include:
- Transport – the site is located by M25, which will allow cost effective transportation. The site is also located near to the Heathrow airport; this will allow cost-effective exports (Products) and imports (Raw materials) while timesaving.
- Labour - The site is relatively near to greater London which has high-density population. Therefore, there will be plentiful labours for the plant, and there is good transport link.
- Site cost – as the land is outside the vicinity of London, the plant cost is very low.
- Utilities and services – the plant site is near to lots of different water supplies such as a river (Thames) and lakes. As the facility, will have high power and steam requirement, this will be available from various sources such as generators and turbines.
Summary of Chapters
1.0 Introduction: Outlines the rising demand for DNA vaccines and the necessity for cGMP-compliant manufacturing facilities to ensure product safety, identity, and purity.
2.0 Detail of the process: Describes the technical stages of pDNA manufacturing, including fermentation, alkaline lysis, chromatography, and product formulation.
3.0 Design of Manufacturing facility: Discusses the strategic selection of the plant location and the layout design aimed at minimizing contamination through controlled material and personnel flows.
4.0 Plant Services, Systems and Utilities: Details the essential infrastructure required, such as HVAC, water purification, and cleaning systems (CIP/SIP) necessary for maintaining sterile environments.
5.0 Process Validation and cGMP: Explains the regulatory necessity of validation protocols and the lifecycle maintenance required to ensure the facility meets quality standards.
6.0 Gannt Chart: Presents the project timeline, utilizing a fast-track approach to synchronize construction, commissioning, and validation activities.
7.0 Costing: Provides an economic evaluation, including capital cost estimations, operational expenditures, and an analysis of the projected return on investment.
8.0 Conclusion: Summarizes the feasibility of the project, concluding that the proposed facility is economically profitable with a short payback period.
Keywords
DNA vaccines, cGMP, manufacturing facility, fermentation, plant design, cleanroom, process validation, HVAC, CIP, SIP, capital cost, ROI, biochemical engineering, pharmaceutical production, plasmid DNA.
Frequently Asked Questions
What is the primary focus of this report?
The report focuses on the conceptual design, technical requirements, and economic feasibility of a new manufacturing plant specifically for DNA vaccine production.
What are the key themes addressed in the documentation?
Key themes include cGMP compliance, process engineering for pDNA, facility layout strategies for contamination control, utility infrastructure, and financial modeling.
What is the central goal of this facility design?
The primary goal is to establish a compliant, efficient, and profitable production site that meets the high-purity requirements for DNA-based gene therapy.
Which scientific methods are applied to the manufacturing process?
The facility employs batch fermentation, alkaline lysis, anion exchange chromatography, gel filtration, and rigorous sterilization (CIP/SIP) protocols.
What is covered in the main body of the work?
The main body covers the technical process description, facility layout, necessary plant utilities (HVAC, water, etc.), validation procedures, and a detailed project schedule.
Which keywords best describe this study?
Core keywords include DNA vaccines, cGMP, process validation, cleanroom classification, and capital cost estimation.
Why is the choice of location considered essential for this facility?
The location in Slough is strategic due to its proximity to London for labor and transport, access to the M25 and Heathrow for logistics, and the availability of necessary utilities.
How does the proposed plant manage the risk of contamination?
Contamination is managed through disciplined plant layouts, strict air quality controls (HEPA filtration), personnel flow management, and the use of Cleaning in Place (CIP) and Sterilize in Place (SIP) systems.
What is the projected economic outcome for the project?
The economic evaluation suggests the project is highly feasible, with a projected payback time of 1.5 years and a significant return on investment.
- Citation du texte
- Sharyar Ahmed (Auteur), 2017, Plant Design and Manufacturing Principles in DNA Vaccine Production, Munich, GRIN Verlag, https://www.grin.com/document/903166
